

## Reaction of 3,3-disubstituted 1-chloromethoxy-1-triazene 2-oxides with tetramethylammonium hydroxide


Gennady A. Smirnov,<sup>\*a</sup> Pavel B. Gordeev,<sup>a</sup> Sergei V. Nikitin,<sup>a</sup> Yulia V. Nelyubina,<sup>b</sup> Galina V. Pokhvisneva,<sup>a</sup> Tatyana V. Ternikova<sup>a</sup> and Oleg A. Luk'yanov<sup>a</sup>

<sup>a</sup> N. D. Zelinsky Institute of Organic Chemistry, Russian Academy of Sciences, 119991 Moscow, Russian Federation. E-mail: smir@ioc.ac.ru

<sup>b</sup> A. N. Nesmeyanov Institute of Organoelement Compounds, Russian Academy of Sciences, 119991 Moscow, Russian Federation

DOI: 10.1016/j.mencom.2017.11.009

The reaction of 3,3-disubstituted 1-chloromethoxy-1-triazene 2-oxides with tetramethylammonium hydroxide results in corresponding [methylenebis(oxy)]bis(1-triazene 2-oxides). Treatment of 1-chloromethoxy-3-(2-hydroxyethyl)-3-methyl-1-triazene 2-oxide with Me<sub>4</sub>NOH gives 16- and 24-membered intermolecular cyclization products.



Nitrogen monoxide NO is one of the versatile required regulators of cellular metabolism functions in living organisms. To date, a broad range of various compounds that can serve as nitrogen monoxide generators in mammalian organisms are reported.<sup>1</sup> On the other hand, intense search for new compounds capable of generating nitrogen monoxide is underway.<sup>2–7</sup> In this context, derivatives of 1-alkoxy-1-triazene 2-oxides which have become known rather recently<sup>8</sup> deserve attention. Some of them are undergoing in-depth biological or preclinical studies as means against diseases of the cardiovascular system, kidneys, pulmonary insufficiency, oncological diseases, and diabetes.<sup>9–11</sup>

Previously,<sup>12–14</sup> we described the synthesis of new alkoxy-triazene oxide derivatives, [methylenebis(oxy)]bis(3,3-dialkyl-1-triazene 2-oxides), *i.e.*, compounds incorporating two oxy-triazene oxide moieties linked through a methylene unit, which are of interest as potential nitrogen monoxide donors. One method involved the alkylation of sodium salts of 1-hydroxy-3,3-dialkyl-1-triazene 2-oxides with chloromethyl ethers of 1-oxy-3,3-dialkyl-1-triazene 2-oxides,<sup>12–14</sup> the other one was the reaction of salts of the same type with dibromomethane.<sup>12</sup> In both cases, the yields of the target compounds did not exceed 30%. In continuation, we have found that treatment of chloromethyl ethers **1a–d** (Scheme 1) with tetramethylammonium hydroxide affords [methylenebis(oxy)]bis(3,3-dialkyl-1-triazene 2-oxides).<sup>†</sup> The yields of products **2** considerably depend on the structure of substituents at 3-position of the chloromethyl ethers **1**. The highest yields were achieved for compounds **2a** (80%) and **2b**

(68%). The presence of *N*-(2-haloethyl) substituents in chloromethyl ethers (**1c,d**) notably drops the yields: 17% for chloroethyl derivative **2c** and 10% for bromoethyl derivative **2d**.


<sup>†</sup> Chloromethyl ethers **1a,b**,<sup>12</sup> **1c–e** and **3**,<sup>13</sup> **1f**<sup>15</sup> were synthesized using reported procedures.

**2,10-Dimethyl-5,7-dioxo-2,3,4,8,9,10-hexaaza-3,8-undecadiene 3,9-dioxide**<sup>12</sup> **2a**. Base Me<sub>4</sub>NOH (0.12 g, 0.66 mmol) was added to compound **1a** (0.1 g, 0.45 mmol) in acetonitrile (5 ml). The mixture was stirred for 5 days at room temperature. The solvent was removed by evaporation. Product **2a** (0.06 g, 83%), mp 62–63 °C, was isolated from the residue using preparative TLC (CHCl<sub>3</sub>–MeOH, 9:1). The spectral characteristics of the product were identical to those reported previously.

**1,7-Di(morpholin-4-yl)-1,2,6,7-tetraaza-3,5-dioxo-1,6-heptadiene 1,7-dioxide**<sup>12</sup> **2b** was obtained similarly from Me<sub>4</sub>NOH (0.071 g, 0.39 mmol) and compound **1b** (0.064 g, 0.33 mmol) in MeCN (3 ml), 20 °C, 3 h. Product **2b** (0.034 g, 68%) was isolated by preparative TLC (ethyl acetate–light petroleum, 2:1), colourless crystals, mp 119–121 °C (EtOH). The spectral characteristics were identical to those reported previously.


**1,13-Dichloro-3,11-dimethyl-6,8-dioxo-3,4,5,9,10,11-hexaazatrideca-4,9-diene 4,10-dioxide** **2c** was obtained similarly from Me<sub>4</sub>NOH (0.08 g, 0.44 mmol) and reactant **1c** (0.038 g, 0.19 mmol) in MeCN (3 ml), 20 °C, 3.5 h. Product **2c** (0.005 g, 17%) was isolated by preparative TLC (ethyl acetate–light petroleum, 1:1). IR (thin layer, ν/cm<sup>–1</sup>): 1502, 1440, 1257, 1067, 1024, 942. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ: 3.16 (s, 6H, 2MeN), 3.69 (m, 8H, 4CH<sub>2</sub>), 5.78 (s, 2H, OCH<sub>2</sub>O). MS (ESI), *m/z*: 319.0683, 321.0654 [M+H]<sup>+</sup>, 336.0948, 338.0919 [M+NH<sub>4</sub>]<sup>+</sup>, 357.0225 [M+K]<sup>+</sup> (calc. for C<sub>7</sub>H<sub>16</sub>Cl<sub>2</sub>N<sub>6</sub>O<sub>4</sub>, *m/z*: 319.0676, 321.0647 [M+H]<sup>+</sup>, 336.0938, 338.0910 [M+NH<sub>4</sub>]<sup>+</sup>, 357.0242 [M+K]<sup>+</sup>).

**1,13-Dibromo-3,11-dimethyl-6,8-dioxo-3,4,5,9,10,11-hexaazatrideca-4,9-diene 4,10-dioxide** **2d** was obtained similarly from Me<sub>4</sub>NOH (0.08 g, 0.44 mmol) and reactant **1d** (0.065 g, 0.22 mmol) in MeCN (3 ml), 20 °C, 3 h. Product **2d** (0.006 g, 11%) was isolated by preparative TLC (ethyl acetate–light petroleum, 1:1). IR (KBr, ν/cm<sup>–1</sup>): 1501, 1440, 1257, 1234, 1066, 1024, 943. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ: 3.15 (s, 6H, 2MeN), 3.50 (t, 4H, 2CH<sub>2</sub>, *J* 6.7 Hz), 3.78 (t, 4H, 2CH<sub>2</sub>, *J* 6.7 Hz), 5.75 (s, 2H, OCH<sub>2</sub>O). MS (ESI), *m/z*: 408.9643 [M+H]<sup>+</sup>, 425.9914 [M+NH<sub>4</sub>]<sup>+</sup>, 428.9487, 430.9464, 432.9442 [M+Na]<sup>+</sup>, 446.9201 [M+K]<sup>+</sup> (calc. for C<sub>7</sub>H<sub>16</sub>Br<sub>2</sub>N<sub>6</sub>O<sub>4</sub>, *m/z*: 408.9652 [M+H]<sup>+</sup>, 425.9918 [M+NH<sub>4</sub>]<sup>+</sup>, 428.9492, 430.9472, 432.9451 [M+Na]<sup>+</sup>, 446.9211 [M+K]<sup>+</sup>).



- a** R<sup>1</sup> = R<sup>2</sup> = Me  
**b** R<sup>1</sup> + R<sup>2</sup> = (CH<sub>2</sub>CH<sub>2</sub>)<sub>2</sub>O  
**c** R<sup>1</sup> = Me, R<sup>2</sup> = CH<sub>2</sub>CH<sub>2</sub>Cl  
**d** R<sup>1</sup> = Me, R<sup>2</sup> = CH<sub>2</sub>CH<sub>2</sub>Br

Scheme 1



Scheme 2

The reaction of interest proceeds ambiguously in the case of acetoxy derivatives **1e,f** (Scheme 2).<sup>‡</sup> Their treatment with Me<sub>4</sub>NOH led to the corresponding diacetate **2e** or tetraacetate **2f**.

<sup>‡</sup> *1,13-Diacetoxy-3,11-dimethyl-6,8-dioxa-3,4,5,9,10,11-hexaazatrieca-4,9-dien-13-ol 4,10-dioxide 2e* and *1-acetoxy-3,11-dimethyl-6,8-dioxa-3,4,5,9,10,11-hexaazatrieca-4,9-dien-13-ol 4,10-dioxide*<sup>14</sup> **2g**.

**Method A.** Base Me<sub>4</sub>NOH (0.036 g, 0.2 mmol) was added with stirring to a solution of compound **1e** (0.038 g, 0.17 mmol) in dry MeCN (3 ml), and the mixture was stirred at 20 °C for 1 h, then the solvent was removed *in vacuo*. Compounds **2e** (0.007 g, 35%) and **2g** (0.007 g, 26%) were isolated as an oil from the residue by preparative TLC with ethyl acetate as the eluent.

**Method B.** Base Me<sub>4</sub>NOH (0.029 g, 0.16 mmol) was added with stirring and ice cooling to a solution of compound **1e** (0.031 g, 0.14 mmol) in dry MeCN (3 ml), the cooling was removed, the reaction mixture was allowed to heat up (~15 min) and stirred at 20 °C for 2 h, then the solvent was removed *in vacuo*. Products **2e** (0.014 g, 56%) and **2g** (0.002 g, 9%) were isolated from the residue by preparative TLC with ethyl acetate as the eluent.

For **2e**: oil. IR (thin layer, ν/cm<sup>-1</sup>): 1741 (CO), 1504, 1448, 1232, 1045, 1024, 940. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ: 2.10 (s, 6H, 2MeCO), 3.16 (s, 6H, 2MeN), 3.70 (t, 4H, 2CH<sub>2</sub>, *J* 7.4 Hz), 4.28 (t, 4H, 2CH<sub>2</sub>, *J* 7.4 Hz), 5.78 (s, 2H, OCH<sub>2</sub>O). MS (ESI), *m/z*: 367.1563 [M+H]<sup>+</sup>, 384.1827 [M+NH<sub>4</sub>]<sup>+</sup>, 389.1378 [M+Na]<sup>+</sup>, 405.1118 [M+K]<sup>+</sup> (calc. for C<sub>11</sub>H<sub>22</sub>N<sub>6</sub>O<sub>8</sub>, *m/z*: 367.1572 [M+H]<sup>+</sup>, 384.1837 [M+NH<sub>4</sub>]<sup>+</sup>, 389.1391 [M+Na]<sup>+</sup>, 405.1131 [M+K]<sup>+</sup>).

For **2g**: oil, the spectral characteristics were identical to those reported previously.

*1,3,11,13-Tetraacetoxy-6,8-dioxa-3,4,5,9,10,11-hexaazatrieca-4,9-dien-13-ol 4,10-dioxide*<sup>16</sup> **2f** and *1,3,11-triacetoxy-6,8-dioxa-3,4,5,9,10,11-hexaazatrieca-4,9-dien-13-ol 4,10-dioxide 2h*.

**Method A.** Base Me<sub>4</sub>NOH (0.015 g, 0.083 mmol) was added with stirring to a solution of reactant **1f** (0.02 g, 0.07 mmol) in dry MeCN (2 ml), and the mixture was stirred at 20 °C for 3 h 20 min, then the solvent was removed *in vacuo*. Products **2f** (0.004 g, 24%) and **2h** (0.005 g, 31%) were isolated as oils by preparative TLC with ethyl acetate as the eluent.

**Method B.** Base Me<sub>4</sub>NOH (0.04 g, 0.22 mmol) was added with stirring and ice cooling to a solution of reactant **1f** (0.05 g, 0.17 mmol) in dry MeCN (4 ml), the cooling was removed, the mixture was allowed to heat up (~15 min) and stirred at 20 °C for 5 h, then the solvent was removed *in vacuo*. Products **2f** (0.024 g, 56%) and **2h** (0.004 g, 10%) were isolated by preparative TLC with ethyl acetate as the eluent.

For **2f**: oil, the spectral characteristics were identical to those reported previously.


For **2h**, oil. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ: 2.10 (s, 9H, 3MeCO), 3.58 (t, 2H, CH<sub>2</sub>), 3.70 (t, 6H, 3CH<sub>2</sub>, *J* 5 Hz), 3.80 (t, 2H, CH<sub>2</sub>), 4.30 (t, 6H, 3CH<sub>2</sub>, *J* 5 Hz), 5.79 (s, 2H, OCH<sub>2</sub>O). MS (ESI), *m/z*: 469.1871 [M+H]<sup>+</sup>, 486.2139 [M+NH<sub>4</sub>]<sup>+</sup>, 491.1693 [M+Na]<sup>+</sup>, 507.1435 [M+K]<sup>+</sup> (calc. for C<sub>15</sub>H<sub>28</sub>N<sub>6</sub>O<sub>11</sub>, *m/z*: 469.1889 [M+H]<sup>+</sup>, 486.2154 [M+NH<sub>4</sub>]<sup>+</sup>, 491.1708 [M+Na]<sup>+</sup>, 507.1448 [M+K]<sup>+</sup>).

However, the process is accompanied by hydrolysis of one acetyl group to give monoacetate **2g** or triacetate **2h**, respectively. The ratio of the products strongly depends on the reaction temperature. At room temperature, compounds **2e** and **2f** are formed in 35 and 24% yields, while the yields of **2g** and **2h** are 26 and 31%, respectively. Lowering the reaction temperature to 0 °C slows down the hydrolysis, and the yields of **2e** and **2f** increase to 56%, whereas those of **2g** and **2h** decrease to 10%.

The formation of symmetric compounds **2** can probably be explained by conversion of chloromethyl ethers **1a–f** into the corresponding salts of hydroxytriazene oxides under the reaction conditions, followed by their reactions with the remaining chloromethyl ether.

The similar reaction of 3-(2-hydroxyethyl)-3-methyl-1-chloromethoxy-1-triazene 2-oxide **3** takes a quite different route (Scheme 3).<sup>§</sup> In this case, intermolecular condensation is followed by cyclization to give the first representatives of oxytriazene *N*-oxides **4**, **5** of two new chemotypes, namely, 16- and 24-membered heterocycles that incorporate two (compound **4**) or three (compound **5**) 1-oxytriazene 2-oxide structural moieties in the ring. The yields of compounds **4** and **5** were 37 and 3%, respectively. Their structures were determined from spectral data and elemental analysis, and confirmed by X-ray single crystal analysis for compound **4** (Figure 1).<sup>¶</sup>

In summary, we have developed a new method for the synthesis of [methylenebis(oxy)]bis(3,3-dialkyl-1-triazene 2-oxides), including previously unknown ones, that allows one to prepare target products in higher yields as compared to the methods




Scheme 3

<sup>§</sup> *4,12-Dimethyl-1,7,9,15-tetraoxa-2,3,4,10,11,12-hexaazacyclohexadeca-2,10-diene 3,11-dioxide 4* and *4,12,20-trimethyl-1,7,9,15,17,23-hexaoxa-2,3,4,10,11,12,18,19,20-nonaazacyclotetradeca-2,10,18-triene 3,11,19-trioxide 5*. Base Me<sub>4</sub>NOH (0.15 g, 0.83 mmol) was added in small portions, with stirring and ice cooling, to a solution of compound **3** (0.128 g, 0.7 mmol) in dry MeCN (7 ml), and the mixture was stirred for 70 min with ice water cooling, then the solvent was removed *in vacuo*. Products **4** (0.038 g, 37%) and **5** (0.003 g, 3%) were isolated by preparative TLC with ethyl acetate as the eluent.

Compound **4**: mp 176–179 °C (EtOH). <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ: 3.15 (s, 6H, 2MeN), 3.65 (t, 4H, 2CH<sub>2</sub>, *J* 4.5 Hz), 3.80 (t, 4H, 2CH<sub>2</sub>, *J* 4.5 Hz), 5.24 (s, 4H, 2CH<sub>2</sub>). MS (ESI), *m/z*: 295.1367 [M+H]<sup>+</sup>, 312.1630 [M+NH<sub>4</sub>]<sup>+</sup>, 317.1178 [M+Na]<sup>+</sup>, 333.0914 [M+K]<sup>+</sup> (calc. for C<sub>8</sub>H<sub>18</sub>N<sub>6</sub>O<sub>6</sub>, *m/z*: 295.1361 [M+H]<sup>+</sup>, 312.1626 [M+NH<sub>4</sub>]<sup>+</sup>, 317.1180 [M+Na]<sup>+</sup>, 333.0919 [M+K]<sup>+</sup>). Found (%): C, 32.58; H, 6.16; N, 28.39. Calc. for C<sub>8</sub>H<sub>18</sub>N<sub>6</sub>O<sub>6</sub> (%): C, 32.65; H, 6.17; N, 28.56.

Compound **5**: <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ: 3.10 (s, 9H, 3MeN), 3.61 (t, 6H, 3CH<sub>2</sub>, *J* 4.9 Hz), 3.90 (t, 6H, 3CH<sub>2</sub>, *J* 4.9 Hz), 5.26 (s, 6H, 3CH<sub>2</sub>). MS (ESI), *m/z*: 442.2007 [M+H]<sup>+</sup>, 459.2279 [M+NH<sub>4</sub>]<sup>+</sup>, 464.1828 [M+Na]<sup>+</sup>, 480.1567 [M+K]<sup>+</sup> (calc. for C<sub>12</sub>H<sub>27</sub>N<sub>9</sub>O<sub>9</sub>, *m/z*: 442.2004 [M+H]<sup>+</sup>, 459.2270 [M+NH<sub>4</sub>]<sup>+</sup>, 464.1824 [M+Na]<sup>+</sup>, 480.1563 [M+K]<sup>+</sup>).



**Figure 1** General view of compound **4** in representation of atoms *via* thermal ellipsoids at 50% probability level. In a crystal, the molecule occupies a special position, *viz.*, the inversion centre.

reported previously. The first two representatives of cyclic analogues have been obtained.

This study was supported by the Russian Science Foundation (project no. 14-50-00126).

## References

1 V. G. Granik and N. B. Grigor'ev, *Oksid azota (NO) [Nitrogen Monoxide (NO)]*, Vuzovskaya Kniga, Moscow, 2004 (in Russian).

<sup>†</sup> *Crystallographic data.* Crystals of **4** ( $C_8H_{18}N_6O_6$ ,  $M = 294.28$ ) are triclinic, space group  $P\bar{1}$ , at 120 K:  $a = 6.5565(13)$ ,  $b = 7.0088(14)$  and  $c = 7.1970(14)$  Å,  $\alpha = 74.562(4)$ ,  $\beta = 86.138(4)$ ,  $\gamma = 84.836(4)^\circ$ ,  $V = 317.17(11)$  Å<sup>3</sup>,  $Z = 1$  ( $Z' = 1/2$ ),  $d_{\text{calc}} = 1.541$  g cm<sup>-3</sup>,  $\mu(\text{MoK}\alpha) = 1.31$  cm<sup>-1</sup>,  $F(000) = 156$ . Intensities of 3948 reflections were measured with a Bruker APEX2 DUO CCD diffractometer [ $\lambda(\text{MoK}\alpha) = 0.71072$  Å,  $\omega$ -scans,  $2\theta < 58^\circ$ ], and 1686 independent reflections ( $R_{\text{int}} = 0.0269$ ) were used in further refinement. The structure was solved by direct method and refined by the full-matrix least-squares technique against  $F^2$  in the anisotropic-isotropic approximation. The positions of hydrogen atoms were calculated, and they were refined in the isotropic approximation within the riding model. The refinement converged to  $wR_2 = 0.1018$  and GOF = 1.035 for all the independent reflections [ $R_1 = 0.0391$  was calculated against  $F$  for 1411 observed reflections with  $I > 2\sigma(I)$ ]. All calculations were performed using SHELXTL PLUS 5.0.<sup>17</sup>

CCDC 1545076 contains the supplementary crystallographic data for this paper. These data can be obtained free of charge from The Cambridge Crystallographic Data Centre *via* <http://www.ccdc.cam.ac.uk>.

- V. P. Ananikov, E. A. Khokhlova, M. P. Egorov, A. M. Sakharov, S. G. Zlotin, A. V. Kucherov, L. M. Kustov, M. L. Gening and N. E. Nifantiev, *Mendeleev Commun.*, 2015, **25**, 75.
- L. L. Fershtat, M. A. Epishina, A. S. Kulikov, M. I. Struchkova and N. N. Makhova, *Chem. Heterocycl. Compd.*, 2015, **51**, 176 (*Khim. Geterotsikl. Soedin.*, 2015, **51**, 176).
- S. G. Zlotin, A. M. Churakov, O. A. Luk'yanov, N. N. Makhova, A. Yu. Sukhorukov and V. A. Tartakovskiy, *Mendeleev Commun.*, 2015, **25**, 399.
- L. L. Fershtat, I. V. Ananyev and N. N. Makhova, *RSC Adv.*, 2015, **5**, 47248.
- M. A. Bastrakov, A. M. Starosotnikov, V. V. Kachala, I. L. Dalinger and S. A. Shevelev, *Chem. Heterocycl. Compd.*, 2015, **51**, 496 (*Khim. Geterotsikl. Soedin.*, 2015, **51**, 496).
- A. A. Voronin, V. P. Zelenov, A. M. Churakov, Yu. A. Strelenko and V. A. Tartakovskii, *Russ. Chem. Bull., Int. Ed.*, 2015, **64**, 699 (*Izv. Akad. Nauk, Ser. Khim.*, 2015, 699).
- Yu. P. Artsybasheva and B. V. Ioffe, *J. Org. Chem. USSR*, 1987, **23**, 1056 (*Zh. Org. Khim.*, 1987, **23**, 1168).
- R. S. Nandurdikar, L. K. Keefer, A. E. Maciag, Z. Cao and J. E. Saavedra, *Bioorg. Med. Chem.*, 2012, **20**, 2025.
- J. Kaur, A. Bhardwaj, Z. Haung, E. E. Knaus, D. Narang, T.-Y. Chen and F. Plane, *J. Med. Chem.*, 2012, **55**, 7883.
- A. Ali, C. Franklin, M. M. Lo and B. R. Whitehead, *US Patent W0 2009/94242 AI*, 2009.
- G. A. Smirnov, P. B. Gordeev, S. V. Nikitin, G. V. Pokhvisneva, T. V. Ternikova and O. A. Luk'yanov, *Russ. Chem. Bull., Int. Ed.*, 2015, **64**, 1057 (*Izv. Akad. Nauk, Ser. Khim.*, 2015, 1057).
- G. A. Smirnov, S. V. Nikitin, P. B. Gordeev, G. V. Pokhvisneva, T. V. Ternikova and O. A. Luk'yanov, *Russ. Chem. Bull., Int. Ed.*, 2015, **64**, 2851 (*Izv. Akad. Nauk, Ser. Khim.*, 2015, 2851).
- G. A. Smirnov, S. V. Nikitin, P. B. Gordeev, G. V. Pokhvisneva, T. V. Ternikova and O. A. Luk'yanov, *Russ. Chem. Bull., Int. Ed.*, 2016, **65**, 2650 (*Izv. Akad. Nauk, Ser. Khim.*, 2016, 2650).
- T. V. Ternikova, G. V. Pokhvisneva, G. A. Smirnov, P. B. Gordeev, S. V. Nikitin and O. A. Luk'yanov, *Russ. Chem. Bull., Int. Ed.*, 2016, **65**, 2873 (*Izv. Akad. Nauk, Ser. Khim.*, 2016, 2873).
- G. A. Smirnov, S. V. Nikitin, P. B. Gordeev, G. V. Pokhvisneva, T. V. Ternikova and O. A. Luk'yanov, *Russ. Chem. Bull., Int. Ed.*, 2016, **65**, 2879 (*Izv. Akad. Nauk, Ser. Khim.*, 2016, 2879).
- G. M. Sheldrick, *Acta Crystallogr., Sect. A*, 2008, **64**, 112.

Received: 20th April 2017; Com. 17/5231